Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study
- PMID: 20962287
- PMCID: PMC2995381
- DOI: 10.1212/WNL.0b013e3181fd6158
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study
Abstract
Objective: To assess prospectively progression and relationship of hallucinations and sleep disorders over a 10-year longitudinal study of patients with Parkinson disease (PD).
Methods: Eighty-nine patients with PD were recruited to fill cells of normal sleep without hallucinations (n = 20), sleep fragmentation only (n = 20), vivid dreams/nightmares (n = 20), hallucinations with insight (n = 20), and hallucinations without insight (n = 9). At baseline, 0.5, 1.5, 4, 6, and 10 years, sleep disorders and hallucinations were assessed by standardized scales with the longitudinal data analyzed by generalized estimating equations with assumptions of linearity in time.
Results: At 10 years, we could account for all subjects (27 interviewed, 61 deceased, and 1 too ill for interview). Hallucination prevalence and severity increased over time (p < 0.0001, p = 0.0001). Acting out dreams also increased over time (p = 0.001). In contrast, presence of vivid dreams/nightmares or sleep fragmentation did not increase over time. For all visits, the prevalence of sleep fragmentation did not differ between subjects with vs without hallucinations (odds ratio [OR] = 1.50, p = 0.09). However, severe sleep fragmentation was associated with concurrent hallucinations (OR 2.01, p = 0.006). The presence of hallucinations was also highly associated with concurrent vivid dreams/nightmares (OR = 2.60, p < 0.0001) and with concurrent acting out dreams (OR = 2.38, p = 0.0004). Among the baseline nonhallucinators, no sleep abnormalities at study entry predicted future development of hallucinations.
Conclusions: Hallucinations and sleep abnormalities follow very different patterns of progression in PD over 10 years. Whereas patients with hallucinations often have concurrent sleep aberrations, no sleep problem is predictive of future hallucinations.
Comment in
-
The importance of longitudinal data on PD, hallucinations, and dream-enacting behaviors.Neurology. 2010 Nov 16;75(20):1762-3. doi: 10.1212/WNL.0b013e3181fd63ab. Epub 2010 Oct 20. Neurology. 2010. PMID: 20962292 No abstract available.
Similar articles
-
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.Neurology. 2005 Jan 11;64(1):81-6. doi: 10.1212/01.WNL.0000148479.10865.FE. Neurology. 2005. PMID: 15642908
-
[Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders].Zhonghua Yi Xue Za Zhi. 2016 Apr 5;96(13):1016-20. doi: 10.3760/cma.j.issn.0376-2491.2016.13.007. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27055793 Chinese.
-
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.Mov Disord. 1999 Jan;14(1):117-21. doi: 10.1002/1531-8257(199901)14:1<117::aid-mds1019>3.0.co;2-0. Mov Disord. 1999. PMID: 9918353
-
Hallucinations and sleep disturbances in Parkinson's disease.Neurology. 2004 Oct 26;63(8 Suppl 3):S28-30. doi: 10.1212/wnl.63.8_suppl_3.s28. Neurology. 2004. PMID: 15505140 Review.
-
Sleep disorder related to Parkinson's disease.J Neurol. 1997 Apr;244(4 Suppl 1):S3-6. doi: 10.1007/BF03160564. J Neurol. 1997. PMID: 9112582 Review.
Cited by
-
The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version.Mov Disord Clin Pract. 2019 Mar 18;6(4):294-301. doi: 10.1002/mdc3.12749. eCollection 2019 Apr. Mov Disord Clin Pract. 2019. PMID: 31061837 Free PMC article.
-
Fatigue is associated with the onset of hallucinations in patients with Parkinson's disease: A 3-year prospective study.eNeurologicalSci. 2016 Apr 16;4:25-29. doi: 10.1016/j.ensci.2016.04.001. eCollection 2016 Sep. eNeurologicalSci. 2016. PMID: 29430545 Free PMC article.
-
Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.Drug Des Devel Ther. 2018 Jul 4;12:2017-2024. doi: 10.2147/DDDT.S160300. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30013321 Free PMC article. Clinical Trial.
-
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease.Parkinsons Dis. 2011 Feb 17;2011:708404. doi: 10.4061/2011/708404. Parkinsons Dis. 2011. PMID: 21403906 Free PMC article.
-
Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.Mov Disord. 2011 Oct;26(12):2190-5. doi: 10.1002/mds.23806. Epub 2011 Jun 28. Mov Disord. 2011. PMID: 21714002 Free PMC article.
References
-
- Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733–745. - PubMed
-
- Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227–2229. - PubMed
-
- Goetz CG, Stebbins GT. Mortality and hallucination in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669–671. - PubMed
-
- Scaravilli T, Gasparoli E, Rinaldi F. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci 2003;24:209–210. - PubMed
-
- Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six year prospective longitudinal study. Neurology 2005;64:81–86. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical